We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+20.38%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$350M
AUM Growth
+$37.4M
Cap. Flow
-$13.1M
Cap. Flow %
-3.75%
Top 10 Hldgs %
66.13%
Holding
48
New
13
Increased
10
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.24M
2
OCUL icon
Ocular Therapeutix
OCUL
+$6.25M
3
ASRT
Assertio
ASRT
+$4.38M
4
PTCT icon
PTC Therapeutics
PTCT
+$3.67M
5
TGTX icon
TG Therapeutics
TGTX
+$3.5M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$16.4M
2
IMMU
Immunomedics Inc
IMMU
+$14.5M
3
BPMC
Blueprint Medicines
BPMC
+$11.6M
4
AXGN icon
Axogen
AXGN
+$7.82M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$6.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.61%
2 Miscellaneous 6.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
1
Axogen
AXGN
$2.78B
$62.6M 17.9%
1,715,000
-255,000
-13% -$7.82M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$55M 15.73%
600,000
-135,000
-18% -$11.6M
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$20.7M 5.92%
179,400
+3,100
+2% +$330K
CDXS icon
4
Codexis
CDXS
$182M
$18.7M 5.35%
1,700,600
– –
KYNB
5
Kyntra Bio
KYNB
$32.4M
$16.6M 4.76%
14,400
– –
SBBP
6
DELISTED
Strongbridge Biopharma plc.
SBBP
$14.1M 4.02%
1,590,000
+340,000
+27% +$2.55M
CORI
7
DELISTED
Corium International, Inc.
CORI
$12.2M 3.49%
1,065,000
+5,000
+0.5% +$60.3K
AGIO icon
8
Agios Pharmaceuticals
AGIO
$2.05B
$10.6M 3.04%
130,000
– –
FENC icon
9
Fennec Pharmaceuticals
FENC
$413M
$10.6M 3.02%
873,000
+26,100
+3% +$247K
SGMO
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.2M 2.91%
535,000
-45,000
-8% -$962K
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$8.64M 2.47%
665,000
– –
DCPH
12
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.31M 2.09%
+365,000
New +$9.24M
OCUL icon
13
Ocular Therapeutix
OCUL
$2.38B
$7.23M 2.07%
+1,111,000
New +$6.25M
XOMA
14
DELISTED
Xoma
XOMA
$6.48M 1.85%
320,200
– –
ARDX icon
15
Ardelyx
ARDX
$986M
$5.73M 1.64%
1,135,600
+235,600
+26% +$1.47M
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
$5.71M 1.63%
190,000
-20,000
-10% -$677K
AMRN
17
Amarin Corp
AMRN
$297M
$5.25M 1.5%
87,250
+44,250
+103% +$3.28M
ABLX
18
DELISTED
Ablynx NV
ABLX
$4.91M 1.4%
90,000
-330,000
-79% -$16.4M
FOMX
19
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.87M 1.39%
950,000
-10,000
-1% -$60.2K
VKTX icon
20
Viking Therapeutics
VKTX
$3.95B
$4.81M 1.38%
1,100,800
+620,242
+129% +$3.43M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.59B
$4.08M 1.17%
80,000
-10,000
-11% -$504K
ACHN
22
DELISTED
Achillion Pharmaceuticals
ACHN
$4.06M 1.16%
1,095,100
+655,100
+149% +$2.14M
ASRT
23
DELISTED
Assertio
ASRT
$3.95M 1.13%
+10,000
New +$4.38M
PTCT icon
24
PTC Therapeutics
PTCT
$5.99B
$3.92M 1.12%
+145,000
New +$3.67M
TGTX icon
25
TG Therapeutics
TGTX
$8.53B
$3.89M 1.11%
+274,200
New +$3.5M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2018 Portfolio in Review

As of Q1 2018, Opaleye Management held 48 positions worth $350M, up 12% from $312M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Opaleye Management withdrew a net $13.1M in Q1 2018, closing 10 positions and reducing 7 holdings. Its most notable exit was Immunomedics Inc, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Deciphera Pharmaceuticals, Inc. Common Stock worth $7.31M.

  • Opaleye Management's largest Q1 2018 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 365,000 shares worth $7.31M.
  • Opaleye Management added most to Viking Therapeutics in Q1 2018, an estimated $3.43M increase.
  • Opaleye Management's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $16.4M.
  • Opaleye Management fully exited Immunomedics Inc in Q1 2018, selling an estimated $14.5M.
  • Opaleye Management's ten largest holdings make up 66% of its $350M portfolio in Q1 2018.
  • Opaleye Management opened 13 new positions and closed 10 in Q1 2018.
  • Opaleye Management's portfolio value rose 12% quarter-over-quarter to $350M.

Based on Opaleye Management's 13F filing for Q1 2018, filed 14 May 2018.